FORM 6-K
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
Reportof Foreign Issuer
Pursuantto Rule 13a-16 or 15d-16 of
theSecurities Exchange Act of 1934
For themonth of May 2024
CommissionFile Number: 001-11960
AstraZeneca PLC
1Francis Crick Avenue
CambridgeBiomedical Campus
CambridgeCB2 0AA
UnitedKingdom
Indicateby check mark whether the registrant files or will file annualreports
under cover of Form 20-F or Form 40-F.
Form20-F X Form 40-F __
Indicateby check mark if the registrant is submitting the Form 6-K in paperas
permitted by Regulation S-T Rule 101(b)(1):
Indicateby check mark if the registrant is submitting the Form 6-K in paperas
permitted by Regulation S-T Rule 101(b)(7): ______
Indicateby check mark whether the registrant by furnishing the informationcontai
ned in this Form is also thereby furnishing the informationto the Commission
pursuant to Rule 12g3-2(b) under the SecuritiesExchange Act of 1934.
Yes __No X
IfYes is marked, indicate below the file numberassigned to the Registrant in
connection with Rule 12g3-2(b):82-_____________
AstraZeneca PLC
INDEXTO EXHIBITS
1.
AstraZeneca to manufacture ADCs in Singapore
20 May 2024
AstraZeneca plans $1.5 billion manufacturing facility
for antibody drug conjugates (ADCs) in Singapore
Operationally ready by 2029, it will be the Company's
first-ever facility to cover the full manufacturing process forADCs
AstraZeneca intends to build a $1.5 billion manufacturing facilityin Singapore
for antibody drug conjugates (ADCs), enhancing globalsupply of its ADC
portfolio. ADCs are next-generation treatmentsthat deliver highly potent
cancer-killing agents directly to cancercells through a targeted antibody.
The planned greenfield facility, supported bythe SingaporeEconomic Development
Board (EDB),will be AstraZeneca's firstend-to-end ADC production site, fully
incorporating all steps ofthe manufacturing process at a commercial scale.
Manufacturing ofADCs is a multi-step process that comprises antibody
production,synthesis of chemotherapy drug and linker, conjugation
ofdrug-linker to the antibody, and filling of the completed ADCsubstance.
Png Cheong Boon, Chairman, EDB said: "We welcome AstraZeneca'sdecision to
establish a manufacturing presence in Singapore for thefirst time. It will
also be a first for AstraZeneca - an end-to-endmanufacturing facility for
novel antibody drug conjugates thatenables precision therapy for cancer. This
greenfield investment isa strong show of confidence in Singapore's
biopharmaceuticalmanufacturing capabilities and talent, strengthens our
ecosystem insupporting the development and manufacturing of precisionmedicines,
and creates meaningful jobs and economic opportunitiesfor Singapore. We look
forward to a successful partnership withAstraZeneca."
Pascal Soriot, Chief Executive Officer, AstraZeneca, said:"AstraZeneca has
built an industry-leading portfolio of cancermedicines including antibody drug
conjugates which have shownenormous potential to replace traditional
chemotherapy for patientsacross many settings. Singapore is one of the world's
mostattractive countries for investment given its reputation forexcellence in
complex manufacturing, and I am excited forAstraZeneca to locate our $1.5
billion ADC manufacturing facilityin the country."
AstraZeneca has a broad portfolio of in-house ADCs including sixwholly owned
ADCs in the clinic and many more in preclinicaldevelopment.
As part of AstraZeneca's commitment to driving sustainability inhealthcare,
the Company will work with Singapore's government andother partners on green
solutions for the ADC facility. Thisfacility will be designed to emit zero
carbon from its first day ofoperations.
AstraZeneca aims to begin design and construction of themanufacturing facility
by the end of 2024, with targetedoperational readiness from 2029.
Notes
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-ledbiopharmaceutical
company that focuses on the discovery,development, and commercialisation of
prescription medicines inOncology, Rare Diseases, and BioPharmaceuticals,
includingCardiovascular, Renal & Metabolism, and Respiratory &Immunology.
Based in Cambridge, UK, AstraZeneca operates in over100 countries and its
innovative medicines are used by millions ofpatients worldwide.Please visit
astrazeneca.com
andfollow the Company on Social Media
@
AstraZeneca
.
Contacts
For details on how to contact the Investor Relations Team, pleaseclick
here
.For Media contacts, click
here
.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuantto the requirements of the Securities Exchange Act of 1934,
theRegistrant has duly caused this report to be signed on its behalfby the
undersigned, thereunto duly authorized.
AstraZenecaPLC
Date:20 May 2024
By: /s/Adrian Kemp
Name:Adrian Kemp
Title:Company Secretary